The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Brad Hively acquired 250,000 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was bought at an average cost of $0.17 per share, for a total transaction of $42,500.00. Following the completion of the transaction, the director now directly owns 616,753 shares of the company's stock, valued at approximately $104,848.01. This trade represents a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Brad Hively also recently made the following trade(s):
- On Monday, December 2nd, Brad Hively purchased 50,000 shares of Oncology Institute stock. The stock was bought at an average price of $0.15 per share, for a total transaction of $7,500.00.
Oncology Institute Trading Down 4.0 %
Shares of TOI stock opened at $0.16 on Tuesday. The Oncology Institute, Inc. has a 12-month low of $0.13 and a 12-month high of $2.50. The company has a market capitalization of $11.75 million, a PE ratio of -0.20 and a beta of 0.60. The firm has a 50 day moving average price of $0.28 and a two-hundred day moving average price of $0.39. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91.
Institutional Trading of Oncology Institute
AI Crypto Tool Could Send One Coin SOARING…
From Crypto 101 Media | Ad
The #1 AI Coin to Buy
Rapid growth predicted for little-known AI crypto project
Discover our #1 crypto pick before it's too late.
![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10814&Placement=NativeDisplay&Source=NativeDisplay)
Hedge funds have recently added to or reduced their stakes in the company. HighTower Advisors LLC increased its position in Oncology Institute by 190.8% during the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company's stock worth $27,000 after acquiring an additional 53,382 shares during the period. Renaissance Technologies LLC grew its position in shares of Oncology Institute by 142.3% during the 2nd quarter. Renaissance Technologies LLC now owns 339,400 shares of the company's stock worth $156,000 after purchasing an additional 199,300 shares in the last quarter. Finally, Tiff Advisory Services LLC increased its holdings in shares of Oncology Institute by 235.1% during the second quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company's stock worth $653,000 after purchasing an additional 995,280 shares during the period. 36.86% of the stock is owned by institutional investors and hedge funds.
About Oncology Institute
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].